Medicare Plans to Cover Aduhelm but With Certain Restrictions

To say that the FDA’s approval of Biogen and Eisai, Co., Ltd.’s Alzheimer’s disease treatment Aduhelm (aducanumab-avwa) on June 7, 2021, garnered an immense amount of attention would seem to be an understatement. That said, the drug has somehow gathered even more notice over the past few months due to multiple developments, with CMS most recently issuing a proposed National Coverage Determination (NCD) on Aduhelm and other monoclonal antibodies that target beta amyloid plaque that will allow Medicare coverage for the therapies but only under certain circumstances. While commercial payers often follow CMS’s lead, it remains to be seen whether that decision — plus a dramatic price cut on Aduhelm — will prompt payers that have declined to cover the therapy to change course.

There is a 30-day public comment period on the proposed NCD, which was published Jan. 11. A final decision is expected on April 11.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-FDA-Extends-Xeljanz-Safety-Warnings-to-Other-JAK-Inhibitors.jpg
January 13

Notable 2021 Approvals Included Oncolytics, Interchangeables

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured-Image_AdobeStock_199469526.jpg
January 13

Many Melanoma Therapies Exist, but Treatment Remains Challenging

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/custom_resized_ffe7ea55-3995-4d73-8e22-55431a9ddcce-scaled.jpeg
January 13

Specialty Pharmacy, Home Infusion Spaces Saw Myriad 2021 Changes

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today